Human Antithrombin III - China Biologic Products

Drug Profile

Human Antithrombin III - China Biologic Products

Alternative Names: ATIII

Latest Information Update: 15 Oct 2016

Price : $50

At a glance

  • Originator Shandong Taibang Biological Products
  • Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Antithrombin III deficiency; Thromboembolism

Most Recent Events

  • 14 Oct 2016 China Food and Drug Administration approves clinical trial application for human antithrombin III to initiate clinical trials in China
  • 11 Oct 2016 Preclinical trials in Antithrombin III deficiency in China (unspecified route) before October 2016
  • 11 Oct 2016 Preclinical trials in Thromboembolism in China (unspecified route) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top